KRAS and non-small cell lung carcinoma: These results help explain why inhibitors of multiple Cdks failed as generic cancer therapies [77] and suggest that focusing instead on a critical kinase (Cdk4) in a specific context (KRAS mutant NSCLC) might be a better approach.